Compare HubSpot Inc (HUBS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs State Street SPDR S&P Biotech ETF — how do they compare? HubSpot Inc trades at $223.72 (market cap $11.84B), while State Street SPDR S&P Biotech ETF trades at $153.23. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | XBI | |
|---|---|---|
Market Cap | $11.84B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $560.90 | $164.28 |
52-Week Low | $170.39 | $85.16 |
Enterprise Value | $10.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.36, up 3.17% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with expanding profit margins. Recent earnings consistently beat expectations, and analyst sentiment remains overwhelmingly positive with 81% buy ratings. Technical indicators show the stock approaching resistance at $232 with RSI levels suggesting potential overbought conditions.
HUBS presents compelling growth prospects with accelerating AI integration and customer expansion, though elevated valuation metrics and competitive pressures warrant caution. The stock's 14% upside to consensus target of $264.06 reflects optimism about continued execution, but investors should monitor margin sustainability and market volatility risks in the software sector.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
